Company Update (NYSE MKT:CUR): Preclinical Data On Neuralstem, Inc.’s Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer’s Disease
Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster “Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer’s Disease” was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden http://neuralstem.com/published-papers. In the poster, researchers from the University of Michigan presented data that mice with an animal model of Alzheimer’s disease (AD), transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Researchers also reported a beta-amyloid plaque reduction in both the cortex and hippocampus of the mice that received the stem cells. Amyloid plaque is one of the two hallmarks of AD.
These results indicate that HK532-IGF-1 transplantation can impact learning and memory deficits, as well as Alzheimer’s pathology. The researchers found the results to be encouraging and recommend further study. HK532-IGF-1, Neuralstem’s second stem cell line, is a proprietary line of cortical neural stem cells engineered to express insulin-like growth factor-1 (IGF-1), which has been shown to have wide-ranging neuroprotective properties. (Original Source)
Shares of Neuralstem closed yesterday at $2.03 . CUR has a 1-year high of $4.62 and a 1-year low of $1.46. The stock’s 50-day moving average is $1.81 and its 200-day moving average is $2.52.
On the ratings front, Neuralstem has been the subject of a number of recent research reports. In a report issued on May 11, Brean Murray Carret analyst Jonathan Aschoff reiterated a Buy rating on CUR, with a price target of $8, which represents a potential upside of 294.1% from where the stock is currently trading. Separately, on March 18, Maxim Group’s Jason Kolbert reiterated a Sell rating on the stock and has a price target of $0.25.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Jason Kolbert have a total average return of 11.8% and 2.3% respectively. Aschoff has a success rate of 56.7% and is ranked #198 out of 3679 analysts, while Kolbert has a success rate of 43.1% and is ranked #1305.
Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.